UA76934C2
(en)
*
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
CA2293632C
(en)
*
|
1997-06-12 |
2011-11-29 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
IL140701A0
(en)
*
|
1998-07-13 |
2002-02-10 |
Univ Texas |
Cancer treatment methods using antibodies to aminophospholipids
|
EP1135498B1
(de)
|
1998-11-18 |
2008-01-23 |
Genentech, Inc. |
Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
|
KR20020093029A
(ko)
|
2000-04-11 |
2002-12-12 |
제넨테크, 인크. |
다가 항체 및 그의 용도
|
SK1152003A3
(en)
*
|
2000-06-29 |
2003-07-01 |
Abbott Lab |
Dual specificity antibodies and methods of making and using
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
EP2163256B1
(de)
|
2001-05-11 |
2015-09-02 |
Ludwig Institute for Cancer Research Ltd. |
Spezifische Bindeproteine und deren Verwendungen
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
US20100081792A1
(en)
*
|
2001-06-28 |
2010-04-01 |
Smithkline Beecham Corporation |
Ligand
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
US7696320B2
(en)
*
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
US9321832B2
(en)
*
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
WO2004003144A2
(en)
|
2002-07-01 |
2004-01-08 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
WO2004015425A1
(en)
|
2002-08-07 |
2004-02-19 |
Umc Utrecht Holding B.V. |
Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
|
CA2505326A1
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
EP1558645B1
(de)
*
|
2002-11-08 |
2011-07-27 |
Ablynx N.V. |
Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
KR101329843B1
(ko)
|
2002-11-15 |
2013-11-14 |
젠맵 에이/에스 |
Cd25에 대한 인간 모노클로날 항체
|
WO2004058184A2
(en)
*
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
MXPA05006043A
(es)
|
2003-01-10 |
2006-01-30 |
Ablynx Nv |
Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
JP2007535895A
(ja)
*
|
2003-05-01 |
2007-12-13 |
イムクローン システムズ インコーポレイティド |
ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体
|
NZ544924A
(en)
|
2003-06-27 |
2009-03-31 |
Biogen Idec Inc |
Modified binding molecules comprising connecting peptides
|
ES2315664T3
(es)
*
|
2003-06-30 |
2009-04-01 |
Domantis Limited |
Anticuerpos de dominio unico (dab) pegilados.
|
EP1531162A1
(de)
*
|
2003-11-14 |
2005-05-18 |
Heinz Vollmers |
Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
|
US8263746B2
(en)
|
2004-02-06 |
2012-09-11 |
Morphosys Ag |
Anti-CD38 human antibodies and uses thereof
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
US20060122377A1
(en)
*
|
2004-02-19 |
2006-06-08 |
Genentech, Inc. |
CDR-repaired antibodies
|
EP1784427A2
(de)
*
|
2004-06-01 |
2007-05-16 |
Domantis Limited |
Bispezifische fusions-antikörper mit erhöhter serumhalbwärtszeit
|
EP1612224B1
(de)
*
|
2004-06-29 |
2012-03-07 |
B.R.A.H.M.S GmbH |
Neue monoklonale Schilddrüsen-stimulierende oder -blockierende Antikörper, korrespondierende Peptidesquenzen ihrer variablen Regionen, und deren Verwendung in Diagnostik, präventiver und therapeutischer Medizin
|
JP2008504356A
(ja)
*
|
2004-06-30 |
2008-02-14 |
ドマンティス リミテッド |
炎症性疾患を治療するための組成物及び方法
|
EP2322554A1
(de)
*
|
2004-06-30 |
2011-05-18 |
Domantis Limited |
Zusammensetzung die ein anti-TNF-alpha Domainantiköper enthält zur Behandlung von Rheumatoide Arthritis
|
WO2006019906A1
(en)
*
|
2004-07-14 |
2006-02-23 |
The Regents Of The University Of California |
Biomarker for early detection of ovarian cancer
|
EP1978032A3
(de)
|
2004-07-22 |
2009-02-18 |
Erasmus University Medical Center Rotterdam |
Bindungsmoleküle
|
CN101072587B
(zh)
|
2004-07-26 |
2012-12-26 |
比奥根艾迪克Ma公司 |
抗-cd154抗体
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
CN101724071A
(zh)
|
2004-10-08 |
2010-06-09 |
杜门蒂斯有限公司 |
抗肿瘤坏死因子受体1的单域抗体及其使用方法
|
EP1799259B1
(de)
*
|
2004-10-12 |
2012-12-05 |
Crucell Holland B.V. |
Bindende moleküle für den nachweis von krebs
|
CN102336832A
(zh)
*
|
2004-11-25 |
2012-02-01 |
荷兰联合利华有限公司 |
重链和结构域抗体
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
CN101133084A
(zh)
*
|
2004-12-02 |
2008-02-27 |
多曼蒂斯有限公司 |
采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
|
CN101128487B
(zh)
*
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
CN101111522A
(zh)
*
|
2004-12-02 |
2008-01-23 |
杜门蒂斯有限公司 |
由于和功能域抗体缀合而具有提高的血清半衰期的plad功能域肽
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
EP1831258B2
(de)
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Monoklonale antikörper gegen nkg2a
|
CN101137673B
(zh)
*
|
2005-01-05 |
2013-12-04 |
比奥根艾迪克Ma公司 |
Cripto结合分子
|
WO2006072625A2
(en)
|
2005-01-06 |
2006-07-13 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
ATE473446T1
(de)
|
2005-01-14 |
2010-07-15 |
Ablynx Nv |
Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
|
NZ556317A
(en)
*
|
2005-01-31 |
2011-01-28 |
Genentech Inc |
Anti-EphB2 antibodies and methods using same
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
JP5167473B2
(ja)
|
2005-03-03 |
2013-03-21 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
抗血管新生化合物
|
MX2007011356A
(es)
|
2005-03-18 |
2008-03-10 |
Domantis Ltd |
Anticuerpos contra antigenos de candida.
|
US8323645B2
(en)
*
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
EP2368995A3
(de)
|
2005-03-25 |
2012-01-18 |
National Research Council of Canada |
Verfahren zur Isolierung von löslichen Polypeptiden
|
US9493569B2
(en)
|
2005-03-31 |
2016-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Structural isomers of sc(Fv)2
|
EP1871417B1
(de)
|
2005-04-15 |
2013-09-11 |
Precision Biologics, Inc. |
Rekombinante monoklonale antikörper und entsprechende antigene für kolon- und pankreaskarzinom
|
MX2007013304A
(es)
*
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
EP2221316A1
(de)
|
2005-05-05 |
2010-08-25 |
Duke University |
CD19-Antikörper-Therapie für Autoimmunerkrankungen
|
ATE537188T1
(de)
|
2005-05-18 |
2011-12-15 |
Ablynx Nv |
Serumalbuminbindende proteine
|
SI2444424T1
(sl)
|
2005-05-20 |
2018-10-30 |
Ablynx N.V. |
Izboljšana protitelesa (TM) za zdravljenje z agregacijo posredovanih motenj
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
WO2006129843A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Canon Kabushiki Kaisha |
Bispecific capturing molecule
|
WO2006129828A2
(en)
|
2005-05-31 |
2006-12-07 |
Canon Kabushiki Kaisha |
Target substance capturing molecule
|
JP2007008925A
(ja)
*
|
2005-05-31 |
2007-01-18 |
Canon Inc |
標的物質捕捉分子
|
CN101262885B
(zh)
|
2005-06-10 |
2015-04-01 |
中外制药株式会社 |
含有sc(Fv)2的药物组合物
|
CA2610987C
(en)
|
2005-06-10 |
2013-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
KR20080047529A
(ko)
*
|
2005-06-17 |
2008-05-29 |
임클론 시스템즈 인코포레이티드 |
전이성 골암 치료를 위한 수용체 길항제
|
EP1912675B1
(de)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-zell-verringerung mit cd37-spezifischen und cd20-spezifischen bindungsmolekülen
|
RU2008110058A
(ru)
*
|
2005-08-15 |
2009-09-27 |
Арана Терапьютикс Лимитед (Au) |
Химерные антитела с областями приматов нового света
|
EP1937814A4
(de)
*
|
2005-09-01 |
2010-05-05 |
Ca Nat Research Council |
Antiapoptotische proteinantikörper
|
KR101472250B1
(ko)
|
2005-10-12 |
2014-12-11 |
모르포시스 아게 |
인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링
|
EP1957531B1
(de)
*
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
|
ES2664854T3
(es)
|
2005-11-14 |
2018-04-23 |
Teva Pharmaceuticals International Gmbh |
Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
CN101432302A
(zh)
|
2005-11-30 |
2009-05-13 |
艾博特公司 |
抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法
|
CA2631195C
(en)
|
2005-11-30 |
2016-04-05 |
Abbott Laboratories |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
EP1957537A2
(de)
*
|
2005-12-01 |
2008-08-20 |
Domantis Limited |
Kompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden
|
BRPI0619225A2
(pt)
*
|
2005-12-01 |
2017-11-07 |
Domantis Ltd |
monômero de anticorpo de domínio, ligando, ácidos nucleicos isolado e recombinante, vetor, célula hospedeira, método para produzir um monômero de dab de ligando, composição farmacêutica, dispositivo de liberação de medicamento, uso de um monômero de anticorpo de domínio, e, método para tratar uma doença inflamatória, artrite ou doença respiratória
|
EA013878B1
(ru)
*
|
2005-12-06 |
2010-08-30 |
Домантис Лимитед |
Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
|
EP1963370A1
(de)
*
|
2005-12-06 |
2008-09-03 |
Domantis Limited |
Bispezifische liganden mit bindungsspezifität für ziele an der zelloberfläche und verfahren zu deren anwendung
|
EP1973948B1
(de)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
ES2291103B1
(es)
|
2005-12-30 |
2009-02-01 |
Universidad Publica De Navarra |
Metodo y sistema de control del convertidor de una instalacion de generacion electrica conectada a una red electrica ante la presencia de huecos de tension en dicha red.
|
EP1806365A1
(de)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
|
WO2007085815A2
(en)
*
|
2006-01-24 |
2007-08-02 |
Domantis Limited |
Ligands that bind il-4 and/or il-13
|
AU2007211829C9
(en)
|
2006-02-01 |
2013-07-11 |
Cephalon Australia Pty Ltd |
Domain antibody construct
|
AU2007212447B2
(en)
*
|
2006-02-03 |
2013-02-21 |
Imclone Llc |
IGF-IR antagonists as adjuvants for treatment of prostate cancer
|
EP1999148B8
(de)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
EP1999147A1
(de)
*
|
2006-03-27 |
2008-12-10 |
Ablynx N.V. |
Medizinisches verabreichungsgerät für therapeutische proteine auf der basis von einzeldomänantikörpern
|
EP4218801A3
(de)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung eines bispezifischen antikörpers
|
US20070269422A1
(en)
*
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
US20070274985A1
(en)
*
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
MX2008015866A
(es)
*
|
2006-06-12 |
2009-01-14 |
Centocor Inc |
Metodo para detectar actividad de interleucina-16 y modulacion de la actividad de interleucina-16 con base en niveles proxi de celulas t normales expresadas y secretadas, reguladas sobre activacion.
|
US8409577B2
(en)
|
2006-06-12 |
2013-04-02 |
Emergent Product Development Seattle, Llc |
Single chain multivalent binding proteins with effector function
|
EP2038306B1
(de)
*
|
2006-06-30 |
2014-12-03 |
Novo Nordisk A/S |
Anti-nkg2a-antikörper und ihre anwendung
|
EP2048163A4
(de)
*
|
2006-07-12 |
2010-07-21 |
Gene Techno Science Co Ltd |
Antihuman-alpha-9-integrinantikörper und dessen verwendung
|
US7741446B2
(en)
*
|
2006-08-18 |
2010-06-22 |
Armagen Technologies, Inc. |
Fusion antibodies that cross the blood-brain barrier in both directions
|
KR101433544B1
(ko)
|
2006-08-18 |
2014-08-27 |
노바르티스 아게 |
Prlr 특이적 항체 및 그 용도
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
JP2010502220A
(ja)
|
2006-09-05 |
2010-01-28 |
メダレックス インコーポレーティッド |
骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
|
EP1900752A1
(de)
*
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Humane anti-Folatrezeptor-alpha Antikörper und -fragmente für die Radioimmuntherapie von Eierstockkrebs
|
GB0619291D0
(en)
*
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
EP2486941B1
(de)
|
2006-10-02 |
2017-03-15 |
E. R. Squibb & Sons, L.L.C. |
CXCR4-bindende humane Antikörper und deren Verwendungen
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
CA2666511A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Ablynx N.V. |
Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
|
CA2665528C
(en)
*
|
2006-10-12 |
2018-01-23 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-ereg antibody
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
ATE520712T1
(de)
|
2006-11-10 |
2011-09-15 |
Covx Technologies Ireland Ltd |
Antiangiogene verbindungen
|
CN103073641B
(zh)
*
|
2006-11-10 |
2015-01-21 |
株式会社立富泰克 |
在体内具有抗肿瘤活性的抗人Dlk-1抗体
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
JP5398538B2
(ja)
|
2006-12-01 |
2014-01-29 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
Cd22に結合するヒト抗体およびその使用
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
RU2448979C2
(ru)
*
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
CA2672581A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
WO2008074839A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
WO2008074840A2
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
US8324350B2
(en)
*
|
2006-12-29 |
2012-12-04 |
Abbott Laboratories |
Dual-specific IL-1α/IL-1β antibodies
|
CN101711284A
(zh)
|
2007-01-25 |
2010-05-19 |
达娜-法勃肿瘤研究所 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
PL2129396T3
(pl)
|
2007-02-16 |
2014-02-28 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
DK2447719T3
(en)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2124952A2
(de)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Verfahren zur behandlung von amyloidosen
|
PL2121920T3
(pl)
*
|
2007-03-01 |
2012-01-31 |
Symphogen As |
Sposób klonowania pokrewnych przeciwciał
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
BRPI0809042B1
(pt)
|
2007-03-22 |
2021-08-31 |
Biogen Ma Inc. |
Proteína de ligação a cd154 isolada, seu uso, e composição
|
EP2132312B1
(de)
|
2007-03-27 |
2016-01-27 |
Sea Lane Biotechnologies,llc. |
Konstrukte und bibliotheken mit antikörper-surrogat-leichtkettensequenzen
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
US9969797B2
(en)
|
2008-04-23 |
2018-05-15 |
Covalent Bioscience Incorporated |
Immunoglobulins directed to bacterial, viral and endogenous polypeptides
|
CA2722304A1
(en)
*
|
2007-04-23 |
2009-02-19 |
Sudhir Paul |
Immunoglobulins directed to bacterial, viral and endogeneous polypeptides
|
EP2164868B1
(de)
*
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
|
US20080279851A1
(en)
|
2007-05-07 |
2008-11-13 |
Medlmmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
AU2008260135A1
(en)
*
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
MX2009013269A
(es)
|
2007-06-05 |
2010-04-21 |
Univ Yale |
Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
|
GB0724331D0
(en)
*
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
CA2688434A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Polypeptides, antibody variable domains and antagonists
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
EP2997976A1
(de)
|
2007-07-27 |
2016-03-23 |
Armagen Technologies, Inc. |
Verfahren und zusammensetzungen zur erhöhung der alpha-iduronidase-aktivität im zns
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
EP2535350B1
(de)
*
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Antikörperfusionen mit Doppelspezifität
|
AU2008320823B2
(en)
|
2007-11-02 |
2013-01-17 |
Novartis Ag |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
|
AU2008329529B2
(en)
|
2007-11-27 |
2015-02-19 |
The University Of British Columbia |
14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
|
AU2008328785A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
SI2851374T1
(sl)
|
2007-12-14 |
2017-08-31 |
Bristol-Myers Squibb Company |
Vezavne molekule k humanemu ox40 receptorju
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
EA021967B1
(ru)
|
2008-01-03 |
2015-10-30 |
Дзе Скриппс Рисерч Инститьют |
Доставка антител посредством модульного домена распознавания
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US9181327B2
(en)
*
|
2008-01-07 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-HIV domain antibodies and method of making and using same
|
SG187457A1
(en)
*
|
2008-01-11 |
2013-02-28 |
Univ Tokyo |
Anti-cldn6 antibody
|
EA028621B1
(ru)
*
|
2008-01-17 |
2017-12-29 |
Новартис Аг |
АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРЫЙ СПЕЦИФИЧНО СВЯЗЫВАЕТ РЕЦЕПТОРНУЮ ТИРОЗИНКИНАЗУ (TrkB), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, И КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ
|
WO2009126350A2
(en)
*
|
2008-01-18 |
2009-10-15 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
JP5774312B2
(ja)
|
2008-01-24 |
2015-09-09 |
ノボ・ノルデイスク・エー/エス |
ヒト化抗ヒトnkg2aモノクローナル抗体
|
CN101959528A
(zh)
|
2008-03-04 |
2011-01-26 |
辉瑞有限公司 |
治疗慢性疼痛的方法
|
CN101965362A
(zh)
|
2008-03-05 |
2011-02-02 |
埃博灵克斯股份有限公司 |
新型抗原结合二聚体-复合物及其制备方法和应用
|
EP2275537B1
(de)
*
|
2008-03-17 |
2014-12-24 |
Livtech Inc. |
Anti-mensch-dlk-1-antikörper mit antikörperaktivität in vivo
|
JP2011515478A
(ja)
*
|
2008-03-25 |
2011-05-19 |
シェーリング コーポレイション |
結腸直腸がんを処置または予防するための方法
|
EP2698380A1
(de)
|
2008-03-28 |
2014-02-19 |
Sea Lane Biotechnologies, LLC |
Neutralisierung von Molekülen in Virusantigene
|
CN107236044B
(zh)
|
2008-04-02 |
2021-07-02 |
宏观基因有限公司 |
HER2/neu-特异性抗体和其使用方法
|
JP2011516520A
(ja)
|
2008-04-07 |
2011-05-26 |
アブリンクス エン.ヴェー. |
Notch経路に指向性を有するアミノ酸配列及びその使用
|
JP6013733B2
(ja)
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
WO2009127691A1
(en)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
DK2280732T3
(en)
*
|
2008-04-28 |
2019-01-28 |
Humanigen Inc |
ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR
|
DK2285408T3
(en)
|
2008-06-05 |
2019-02-04 |
Ablynx Nv |
AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
|
CA2728733A1
(en)
*
|
2008-06-18 |
2009-12-23 |
California Institute Of Technology |
Multi-ligand capture agents and related compositions, methods and systems
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
MX2011000501A
(es)
|
2008-07-18 |
2011-05-23 |
Squibb Bristol Myers Co |
Composiciones monovalentes para union a cd28 y metodos de uso.
|
EP2316030B1
(de)
|
2008-07-25 |
2019-08-21 |
Wagner, Richard W. |
Proteinscreeningverfahren
|
BRPI0917871A2
(pt)
|
2008-08-15 |
2017-06-20 |
Merrimack Pharmaceuticals Inc |
agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
|
WO2010027767A1
(en)
*
|
2008-08-27 |
2010-03-11 |
Schering Corporation |
Engineered anti-il-23r antibodies
|
AU2009288167B2
(en)
|
2008-09-03 |
2015-10-22 |
Genentech, Inc. |
Multispecific antibodies
|
WO2010027488A2
(en)
*
|
2008-09-04 |
2010-03-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies
|
PL2334705T3
(pl)
*
|
2008-09-26 |
2017-06-30 |
Ucb Biopharma Sprl |
Produkty biologiczne
|
AU2009299794B2
(en)
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
CN102272155B
(zh)
*
|
2008-10-13 |
2018-05-25 |
生物医学研究所 |
登革热病毒中和抗体及其用途
|
EP2346900A1
(de)
|
2008-10-29 |
2011-07-27 |
Wyeth LLC |
Verfahren zur aufreinigung von einzeldomänantigenbindenden molekülen
|
CN104740631B
(zh)
|
2008-10-29 |
2019-04-16 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
EA029178B1
(ru)
|
2008-12-12 |
2018-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение
|
DK2387583T3
(en)
|
2009-01-14 |
2019-01-14 |
Ablynx Nv |
PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
|
WO2010084408A2
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
SG2014007637A
(en)
*
|
2009-01-29 |
2014-03-28 |
Medimmune Llc |
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
|
EP2393836A4
(de)
*
|
2009-02-09 |
2012-09-26 |
Patrys Ltd |
Sam-6 varianten, target und verwendungsverfahren
|
WO2010094720A2
(en)
|
2009-02-19 |
2010-08-26 |
Glaxo Group Limited |
Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
EP3330287B1
(de)
|
2009-02-19 |
2019-12-18 |
Glaxo Group Limited |
Verbesserte anti-serumalbumin-bindende varianten
|
PE20120170A1
(es)
|
2009-02-19 |
2012-03-21 |
Glaxo Group Ltd |
Variantes de union a anti-albumina de suero mejoradas
|
US20110305692A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Antigen-binding contructs
|
HUE034196T2
(en)
|
2009-03-05 |
2018-02-28 |
Squibb & Sons Llc |
Fully human antibodies specific for CADM1
|
EP2403873A1
(de)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
|
US9533055B2
(en)
|
2009-03-18 |
2017-01-03 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
US8569460B2
(en)
|
2009-03-25 |
2013-10-29 |
Vet Therapeutics, Inc. |
Antibody constant domain regions and uses thereof
|
RU2598248C2
(ru)
*
|
2009-04-02 |
2016-09-20 |
Роше Гликарт Аг |
Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
|
EP2417156B1
(de)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalente, bispezifische antikörper
|
EP2417163B1
(de)
|
2009-04-10 |
2019-02-27 |
Ablynx N.V. |
Verbesserte, gegen il-6r gerichtete aminosauresequenzen und polypeptide, die diese enthalten, zur behandlung von erkrankungen und storungen, die mit il-6r in zusammenhang stehen
|
KR101736076B1
(ko)
|
2009-04-20 |
2017-05-16 |
옥스포드 바이오테라퓨틱스 리미티드 |
카드헤린-17에 특이적인 항체
|
US20120058116A1
(en)
|
2009-04-24 |
2012-03-08 |
Andrew Beaton |
Fgfr1c antibody combinations
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
EP2436397B1
(de)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmazeutische zusammensetzung mit einem antagonisten eines liganden der egf-familie als bestandteil
|
HUE035773T2
(en)
|
2009-06-05 |
2018-05-28 |
Ablynx Nv |
Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
KR101962476B1
(ko)
*
|
2009-07-03 |
2019-03-26 |
아비펩 피티와이 리미티트 |
면역성 접합체 및 그 제조방법
|
CA2768460A1
(en)
|
2009-07-16 |
2011-01-20 |
Glaxo Group Limited |
Antagonists, uses & methods for partially inhibiting tnfr1
|
BR112012001681A2
(pt)
|
2009-07-16 |
2019-09-24 |
Graxo Group Ltd |
domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
|
KR20120063475A
(ko)
|
2009-07-29 |
2012-06-15 |
글락소 그룹 리미티드 |
항-tgf-베타 수용체 타입 ⅱ 단일 도메인 항체
|
CA2771186C
(en)
|
2009-08-28 |
2018-01-02 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
PE20121647A1
(es)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
US9109216B2
(en)
|
2009-09-24 |
2015-08-18 |
Ucb Pharma, S.A. |
Bacterial host strain
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
DK2485761T3
(da)
|
2009-10-09 |
2019-05-06 |
Armagen Inc |
Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
EP2470569A1
(de)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antikörper gegen epha10
|
ES2552177T3
(es)
|
2009-10-27 |
2015-11-26 |
Glaxo Group Limited |
Polipéptidos anti-TNFR1 estables, dominios variables de anticuerpos y antagonistas
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
JP2013509869A
(ja)
|
2009-11-05 |
2013-03-21 |
ノバルティス アーゲー |
線維症の進行の予測用バイオマーカー
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
CN102711449B
(zh)
|
2009-12-10 |
2015-01-07 |
瑞泽恩制药公司 |
生产重链抗体的小鼠
|
WO2011073180A1
(en)
|
2009-12-14 |
2011-06-23 |
Ablynx N.V. |
Single variable domain antibodies against ox40l, constructs and therapeutic use
|
KR101961495B1
(ko)
*
|
2009-12-23 |
2019-03-22 |
아비펩 피티와이 리미티트 |
면역-컨쥬게이트 및 그 제조방법 2
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
GB201000591D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
GB201000590D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
SI3295957T1
(sl)
|
2010-01-15 |
2020-02-28 |
Kirin-Amgen, Inc. |
Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
CA2788993A1
(en)
|
2010-02-05 |
2011-08-11 |
Ablynx N.V. |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
EP2534489A1
(de)
|
2010-02-10 |
2012-12-19 |
Novartis AG |
Verfahren und verbindungen für muskelwachstum
|
WO2011098518A2
(en)
|
2010-02-11 |
2011-08-18 |
Ablynx Nv |
Delivery of immunoglobulin variable domains and constructs thereof
|
WO2011109298A2
(en)
|
2010-03-02 |
2011-09-09 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
US9616120B2
(en)
|
2010-03-04 |
2017-04-11 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD20
|
AU2011223547B2
(en)
|
2010-03-04 |
2016-05-05 |
Vet Therapeutics, Inc. |
Monoclonal antibodies directed to CD52
|
EP2859893A1
(de)
|
2010-03-11 |
2015-04-15 |
Merrimack Pharmaceuticals, Inc. |
Verwendung von ERBB3-Hemmern bei der Behandlung von dreifach negativem und basalem Brustkrebs
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
CN102947335B
(zh)
|
2010-04-15 |
2018-11-06 |
基因泰克公司 |
抗多聚遍在蛋白抗体及使用方法
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
WO2011131659A2
(en)
|
2010-04-21 |
2011-10-27 |
Glaxo Group Limited |
Binding domains
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
CN103237811A
(zh)
|
2010-05-06 |
2013-08-07 |
诺瓦提斯公司 |
用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
JP2013529080A
(ja)
|
2010-05-20 |
2013-07-18 |
グラクソ グループ リミテッド |
改良された抗血清アルブミン結合変異体
|
WO2011163401A2
(en)
|
2010-06-22 |
2011-12-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
EP3960865A1
(de)
|
2010-08-02 |
2022-03-02 |
Regeneron Pharmaceuticals, Inc. |
Mäuse, die bindeproteine mit vl-domänen produzieren
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
AU2011288412A1
(en)
|
2010-08-13 |
2013-02-21 |
Medimmune Limited |
Monomeric polypeptides comprising variant Fc regions and methods of use
|
US9012609B2
(en)
|
2010-08-13 |
2015-04-21 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-serum albumin binding variants
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
BR112013003899A2
(pt)
|
2010-08-20 |
2016-06-07 |
Glaxosmithkline Ip Dev Ltd |
domínio variável único da imunoglobina anti-albumina sérica (sa), ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, método de tratar ou previnir uma doença ou distúrbio em um paciente
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
SI2606070T1
(sl)
|
2010-08-20 |
2017-04-26 |
Novartis Ag |
Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CN105481983B
(zh)
|
2010-09-09 |
2021-09-03 |
辉瑞公司 |
4-1bb结合分子
|
TWI619811B
(zh)
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
WO2012069655A2
(en)
|
2010-11-26 |
2012-05-31 |
Molecular Partners Ag |
Improved n-terminal capping modules for designed ankyrin repeat proteins
|
PL2647707T3
(pl)
*
|
2010-11-30 |
2019-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Środek terapeutyczny wywołujący cytotoksyczność
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
EP2646467A2
(de)
|
2010-12-01 |
2013-10-09 |
Glaxo Group Limited |
Verbesserte antiserumalbuminbindende variable einzeldomänen
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
EP3434691A1
(de)
|
2010-12-01 |
2019-01-30 |
AlderBio Holdings LLC |
Anti-ngf-zusammensetzengen und ihre verwendung
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
WO2012091564A2
(en)
*
|
2010-12-27 |
2012-07-05 |
Apo-T B.V. |
A cross-linking polypeptide that induces apoptosis
|
ES2627299T3
(es)
|
2011-01-06 |
2017-07-27 |
Glaxo Group Limited |
Ligandos que se unen al receptor II del TGF-beta
|
US20130310281A1
(en)
|
2011-02-02 |
2013-11-21 |
Glaxo Group Limited |
Novel antigen binding proteins
|
EP2673297A2
(de)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalente und multivalente multispezifische komplexe und verwendungen davon
|
EP2681239B8
(de)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigenbindende proteine
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
BR112013023918A2
(pt)
*
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
SG193552A1
(en)
|
2011-03-30 |
2013-11-29 |
Boehringer Ingelheim Int |
Anticoagulant antidotes
|
AU2012237287B2
(en)
|
2011-03-30 |
2016-09-08 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against TNF-alpha
|
WO2012135831A1
(en)
|
2011-04-01 |
2012-10-04 |
Yale University |
Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
NZ717704A
(en)
|
2011-05-20 |
2022-08-26 |
H Lundbeck As |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
RS61793B1
(sr)
|
2011-05-20 |
2021-06-30 |
H Lundbeck As |
Anti-cgrp kompozicije i njihova upotreba
|
DK2709663T3
(da)
|
2011-05-20 |
2019-05-20 |
Alderbio Holdings Llc |
Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
CA2835340A1
(en)
|
2011-05-27 |
2012-12-06 |
Ablynx Nv |
Inhibition of bone resorption with rankl binding peptides
|
US9580480B2
(en)
|
2011-05-31 |
2017-02-28 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
BR112013032217B1
(pt)
|
2011-06-17 |
2021-01-19 |
Novo Nordisk A/S |
uso de um anticorpo anti-nkg2a
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
PL2726508T3
(pl)
|
2011-06-28 |
2017-12-29 |
Oxford Biotherapeutics Ltd |
Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
|
WO2013001369A2
(en)
|
2011-06-28 |
2013-01-03 |
Oxford Biotherapeutics Ltd. |
Therapeutic and diagnostic target
|
US8951966B2
(en)
|
2011-07-01 |
2015-02-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
|
LT2731973T
(lt)
|
2011-07-13 |
2018-02-26 |
Ucb Biopharma Sprl |
Bakterijų padermė, ekspresuojanti rekombinantinį dsbc
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
US9321844B2
(en)
|
2011-08-05 |
2016-04-26 |
Genentech, Inc. |
Anti-polyubiquitin antibodies
|
MX2014001883A
(es)
*
|
2011-08-17 |
2014-05-27 |
Glaxo Group Ltd |
Proteinas y peptidos modificados.
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
MY173865A
(en)
|
2011-09-22 |
2020-02-25 |
Amgen Inc |
Cd27l antigen binding proteins
|
US9399678B2
(en)
*
|
2011-09-23 |
2016-07-26 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Anti-tumor necrosis factor-alpha agents and uses thereof
|
EP3311837A1
(de)
|
2011-09-23 |
2018-04-25 |
Ablynx NV |
Verlängerte hemmung der interleukin-6-vermittelten signalisierung
|
JP2014530009A
(ja)
|
2011-09-29 |
2014-11-17 |
エーピーオー‐ティー ビー.ヴイ. |
異常細胞を標的とする多重特異性結合分子
|
EP2760530B1
(de)
|
2011-09-30 |
2018-10-24 |
Nyxoah SA |
Vorrichtung zur steuerung eines implantats
|
US9127056B2
(en)
|
2011-10-17 |
2015-09-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
|
WO2013060872A1
(en)
|
2011-10-27 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Anticancer combination therapy
|
RU2681885C2
(ru)
|
2011-10-31 |
2019-03-13 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
|
WO2013067054A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
MX2014005411A
(es)
|
2011-11-04 |
2015-02-12 |
Novartis Ag |
Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
|
PL2776466T3
(pl)
|
2011-11-11 |
2018-01-31 |
Ucb Biopharma Sprl |
Przeciwciała wiążące albuminę i ich fragmenty wiążące
|
JP6266529B2
(ja)
|
2011-12-02 |
2018-01-24 |
アーマジェン・インコーポレイテッドArmagen, Inc. |
Cnsにおけるアリールスルファターゼa活性を増加するための方法および組成物
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
ES2758433T3
(es)
|
2011-12-05 |
2020-05-05 |
Novartis Ag |
Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
|
BR112014015238B1
(pt)
|
2011-12-20 |
2022-11-16 |
Regeneron Pharmaceuticals, Inc |
Método ex vivo para preparar um anticorpo que se liga a um antígeno de interesse compreendendo identificar sequências de ácido nucleico a partir de linfócitos b de camundongo geneticamente modificado pela colocação de um gene adam6
|
EP3446707A1
(de)
|
2011-12-22 |
2019-02-27 |
i2 Pharmaceuticals, Inc. |
Surrogatbindungsproteine
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CA2860914A1
(en)
|
2012-01-13 |
2013-07-18 |
Apo-T B.V. |
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
|
RU2693264C2
(ru)
*
|
2012-02-03 |
2019-07-01 |
Ф.Хоффман-Ля Рош Аг |
Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине
|
MX2014009565A
(es)
*
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
GB201203071D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
KR101505157B1
(ko)
*
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
EP2852404B1
(de)
*
|
2012-05-21 |
2017-07-26 |
Genentech, Inc. |
ANTI-Ly6E-ANTIKÖRPER UND -IMMUNKONJUGATE UND VERFAHREN ZUR VERWENDUNG
|
CA2869529A1
(en)
*
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
US11339208B1
(en)
|
2012-05-31 |
2022-05-24 |
United States Of America As Represented By The Secretary Of The Air Force |
Camelidae single-domain antibodies against Yersinia pestis and methods of use
|
MX2014014804A
(es)
|
2012-06-27 |
2015-02-12 |
Hoffmann La Roche |
Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US20150203591A1
(en)
*
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
EP2888279A1
(de)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti-lrp6-antikörper
|
EP2905335B1
(de)
|
2012-10-03 |
2018-01-31 |
Chiome Bioscience Inc. |
Antikörper gegen menschliches dlk-1 mit in-vivo-antitumorwirkung
|
TW201811825A
(zh)
|
2012-11-01 |
2018-04-01 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
ES2828505T3
(es)
|
2012-11-28 |
2021-05-26 |
Ngm Biopharmaceuticals Inc |
Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
|
ES2784631T3
(es)
|
2012-12-03 |
2020-09-29 |
Novimmune Sa |
Anticuerpos anti-CD47 y métodos de uso de los mismos
|
JP2016500367A
(ja)
|
2012-12-05 |
2016-01-12 |
デュタリス ゲーエムベーハー |
デュアルターゲティング
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
IL292303A
(en)
|
2012-12-27 |
2022-06-01 |
Ngm Biopharmaceuticals Inc |
Methods of regulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
WO2014111550A1
(en)
|
2013-01-17 |
2014-07-24 |
Glaxosmithkline Intellectual Property Development Limited |
Modified anti-serum albumin binding proteins
|
EP2948478B1
(de)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antikörper gegen cdh19 für melanome
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
US9701743B2
(en)
|
2014-02-20 |
2017-07-11 |
Allergan, Inc. |
Complement component C5 antibodies
|
EP2962100B1
(de)
|
2013-02-28 |
2021-07-28 |
Caprion Proteomics Inc. |
Tuberkulose biomarker und deren verwendung
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
AR095374A1
(es)
*
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
AU2014236769B2
(en)
*
|
2013-03-15 |
2018-09-27 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
WO2014144573A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Multimerization technologies
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
MX2015013288A
(es)
|
2013-03-18 |
2016-04-07 |
Biocerox Prod Bv |
Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
|
ES2973474T3
(es)
|
2013-05-30 |
2024-06-20 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de enlace a antígeno del receptor de oncostatina M
|
US10174117B2
(en)
*
|
2013-06-11 |
2019-01-08 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
|
AU2014292924B2
(en)
*
|
2013-07-25 |
2019-11-21 |
Cytomx Therapeutics, Inc |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
KR102048718B1
(ko)
|
2013-08-02 |
2019-11-26 |
화이자 인코포레이티드 |
항-cxcr4 항체 및 항체-약물 접합체
|
RU2661087C2
(ru)
*
|
2013-08-30 |
2018-07-11 |
Априлбио Ко., Лтд |
Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину, и эффекторный компонент, и способы ее получения
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN113667013B
(zh)
|
2013-10-02 |
2024-04-09 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
EP3055329B1
(de)
|
2013-10-11 |
2018-06-13 |
F. Hoffmann-La Roche AG |
Multispezifische antikörper mit domänengetauschten, gemeinsamen, variablen leichten ketten
|
KR102178323B1
(ko)
*
|
2013-11-29 |
2020-11-13 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
KR102597804B1
(ko)
*
|
2013-12-20 |
2023-11-07 |
제넨테크, 인크. |
이중 특이적 항체
|
EP3087394A2
(de)
|
2013-12-27 |
2016-11-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarkerprofile zur vorhersage der ergebnisse einer krebstherapie mit erbb3-inhibitoren und/oder chemotherapien
|
WO2015130826A1
(en)
|
2014-02-27 |
2015-09-03 |
Allergan, Inc. |
COMPLEMENT FACTOR Bb ANTIBODIES
|
WO2015143414A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
SI3119431T1
(sl)
|
2014-03-21 |
2024-06-28 |
Teva Pharmaceuticals International Gmbh |
Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
|
EP3119811B1
(de)
|
2014-03-21 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen-bindende proteine mit unterschiedlichen bindungseigenschaften
|
AU2015240599B2
(en)
|
2014-04-04 |
2020-11-19 |
Bionomics, Inc. |
Humanized antibodies that bind LGR5
|
ES2900898T3
(es)
|
2014-04-07 |
2022-03-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecíficos inmunoactivadores
|
DK3129470T3
(da)
*
|
2014-04-07 |
2021-07-05 |
Novartis Ag |
Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
|
CA2947157A1
(en)
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
RS60717B1
(sr)
|
2014-05-16 |
2020-09-30 |
Ablynx Nv |
Varijabilni domeni imunoglobulina
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
US10238742B2
(en)
*
|
2014-06-25 |
2019-03-26 |
Yale University |
Cell penetrating nucleolytic antibody based cancer therapy
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス,インコーポレイティド |
抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
AR101669A1
(es)
*
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
KR102259232B1
(ko)
*
|
2014-08-25 |
2021-05-31 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
US10517929B2
(en)
|
2014-10-23 |
2019-12-31 |
Ngm Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising FGF19 variants
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
EP3218398A1
(de)
*
|
2014-11-10 |
2017-09-20 |
F. Hoffmann-La Roche AG |
Anti-ang2-antikörper und verfahren zur verwendung
|
JP2017537896A
(ja)
|
2014-11-10 |
2017-12-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗体及び眼科に使用する方法
|
RU2017120358A
(ru)
|
2014-11-10 |
2018-12-13 |
Ф.Хоффманн-Ля Рош Аг |
Анти-il-1-бета антитела и способы их применения
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
WO2016097313A1
(en)
|
2014-12-19 |
2016-06-23 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
WO2016124781A1
(en)
*
|
2015-02-05 |
2016-08-11 |
Ablynx N.V. |
Nanobody dimers linked via c-terminally engineered cysteins
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
AU2016263808B2
(en)
|
2015-05-21 |
2019-01-03 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
KR20180053322A
(ko)
|
2015-09-21 |
2018-05-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス,インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
MX2018007781A
(es)
|
2015-12-28 |
2018-09-05 |
Chugai Pharmaceutical Co Ltd |
Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
|
KR20180116215A
(ko)
|
2016-03-14 |
2018-10-24 |
추가이 세이야쿠 가부시키가이샤 |
암의 치료에 이용하기 위한 세포상해 유도 치료제
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
JP2019510786A
(ja)
|
2016-04-05 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
免疫療法におけるTGFβの阻害
|
RS61510B1
(sr)
|
2016-05-18 |
2021-03-31 |
Boehringer Ingelheim Int |
Anti pd-1 i anti-lag3 antitela za lečenje kancera
|
AU2017268460B2
(en)
|
2016-05-20 |
2023-12-14 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
CA3024683A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
KR102461666B1
(ko)
|
2016-06-03 |
2022-11-01 |
얀센 바이오테크 인코포레이티드 |
혈청 알부민 결합 피브로넥틴 iii 형 도메인
|
JP2019518040A
(ja)
|
2016-06-15 |
2019-06-27 |
イェール ユニバーシティーYale University |
腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
CN109661406A
(zh)
|
2016-07-29 |
2019-04-19 |
国家医疗保健研究所 |
靶向肿瘤相关巨噬细胞的抗体及其用途
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
CN109952314A
(zh)
|
2016-09-23 |
2019-06-28 |
泰瓦制药国际有限公司 |
治疗难治性偏头痛
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
BR112019010061A2
(pt)
|
2016-11-16 |
2019-08-13 |
Ablynx Nv |
polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
|
CA3044659A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
|
IL310340A
(en)
|
2016-12-07 |
2024-03-01 |
Ablynx Nv |
Immunoglobulin sites with a single variable enhance serum albumin binding
|
EP3360898A1
(de)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispezifische, an tnf-related apoptosis-inducing ligand receptor 2 und cadherin 17 bindende, bindungsmoleküle zur behandlung von krebs
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
JP7300385B2
(ja)
|
2017-01-17 |
2023-06-29 |
アブリンクス エン.ヴェー. |
改善された血清アルブミン結合剤
|
BR112019014599A2
(pt)
|
2017-01-17 |
2020-03-03 |
Ablynx N.V. |
Ligantes de albumina sérica melhorados
|
AU2018214554C1
(en)
|
2017-02-01 |
2022-12-15 |
Novo Nordisk A/S |
Treatment of diuretic resistance
|
EP3589662A4
(de)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
Induzierbares monovalentes antigenbindendes protein
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
KR20200026810A
(ko)
|
2017-05-12 |
2020-03-11 |
하푼 테라퓨틱스, 인크. |
Msln 표적화 삼중 특이적 단백질 및 사용 방법
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
メソテリン結合タンパク質
|
UA125761C2
(uk)
*
|
2017-05-31 |
2022-06-01 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Поліпептид, який перешкоджає передачі wnt-сигналів у пухлинних клітинах
|
IL253015B2
(en)
|
2017-06-18 |
2023-07-01 |
Israel Aerospace Ind Ltd |
System and method for refueling aerial vehicles
|
IL253407B
(en)
|
2017-07-10 |
2020-08-31 |
Israel Aerospace Ind Ltd |
refueling station
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
EP3470426A1
(de)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispezifischer antikörper
|
MX2020003562A
(es)
|
2017-10-10 |
2020-10-01 |
Numab Therapeutics AG |
Anticuerpo multiespecifico.
|
SG11202003359UA
(en)
|
2017-10-13 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific proteins and methods of use
|
EA202090739A1
(ru)
|
2017-10-13 |
2020-09-07 |
Харпун Терапьютикс, Инк. |
Белки, связывающие антиген созревания в-клеток
|
US11472889B2
(en)
|
2017-10-14 |
2022-10-18 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
EP3728328A1
(de)
|
2017-12-22 |
2020-10-28 |
Argenx BVBA |
Bispezifisches antigenbindendes konstrukt
|
JP7395479B2
(ja)
|
2018-01-05 |
2023-12-11 |
ノヴォ ノルディスク アー/エス |
免疫抑制なしにil-6媒介性炎症を処置する方法
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
EP3569618A1
(de)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonisierender cd73-antikörper
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
EP3849602A1
(de)
|
2018-09-10 |
2021-07-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
EP3870608A1
(de)
|
2018-10-25 |
2021-09-01 |
Polpharma Biologics Utrecht B.V. |
Anti-human-cd89-antikörper und verwendungen davon
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
WO2020114615A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
WO2020115283A1
(en)
*
|
2018-12-07 |
2020-06-11 |
Baxalta GmbH |
Bispecific antibodies binding factor ixa and factor x
|
WO2020146527A1
(en)
|
2019-01-08 |
2020-07-16 |
Alder Biopharmaceuticals, Inc. |
Acute treatment and rapid treatment of headache using anti-cgrp antibodies
|
JP2022526334A
(ja)
|
2019-03-25 |
2022-05-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
新たなタウ種を標的化することによるタウオパチー障害の処置の方法
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
US20220324962A1
(en)
|
2019-09-27 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
EP3816185A1
(de)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispezifischer antikörper gegen pd-l1 und ein tumorassoziiertes antigen
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
BR112022012725A2
(pt)
|
2019-12-24 |
2022-11-16 |
Jjp Biologics Sp Z O O |
Anticorpos hvem (tnfrsf14) anti-humanos e usos dos mesmos
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
BR112022016550A2
(pt)
|
2020-02-21 |
2022-11-16 |
Harpoon Therapeutics Inc |
Proteínas de ligação a flt3 e métodos de uso
|
EP4133084A1
(de)
|
2020-04-09 |
2023-02-15 |
Autolus Limited |
Polypeptid
|
KR20230004739A
(ko)
|
2020-04-21 |
2023-01-06 |
제이제이피 바이오로직스 에스피. 제트 오.오. |
인간화 항-인간 cd89 항체 및 이의 용도
|
CN115551553A
(zh)
|
2020-05-12 |
2022-12-30 |
Inserm(法国国家健康医学研究院) |
治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
GB202007441D0
(en)
|
2020-05-19 |
2020-07-01 |
Autolus Ltd |
Polypeptide
|
EP3915580A1
(de)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispezifischer antikörper
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
EP4206224A1
(de)
|
2020-08-26 |
2023-07-05 |
National University Corporation Kumamoto University |
Menschlicher antikörper oder antigenbindendes fragment davon gegen coronavirus-spike-protein
|
WO2022084355A2
(en)
|
2020-10-21 |
2022-04-28 |
Boehringer Ingelheim International Gmbh |
Agonistic trkb binding molecules for the treatment of eye diseases
|
EP3988568A1
(de)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Kombinationsbehandlung
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
WO2022098745A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, delivery systems, and methods useful in tumor therapy
|
AU2021395729A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
WO2022167460A1
(en)
|
2021-02-02 |
2022-08-11 |
Numab Therapeutics AG |
Multispecific antibodies having specificity for ror1 and cd3
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
CN117957256A
(zh)
|
2021-06-17 |
2024-04-30 |
勃林格殷格翰国际有限公司 |
新颖三特异性结合分子
|
EP4183800A1
(de)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Neue sars-cov-2-neutralisierende antikörper
|
WO2023116861A1
(zh)
|
2021-12-23 |
2023-06-29 |
江苏恒瑞医药股份有限公司 |
抗dll3抗体、其抗体-药物偶联物及其医药用途
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023196932A2
(en)
*
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of California |
Isolating active t-cell cars from bulk transduced human t-cells
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
WO2024170756A1
(en)
|
2023-02-17 |
2024-08-22 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|